|
FBXL17 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.15623091498674E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.28386231937839E-14 |
| Normal-vs-Stage2 |
8.660200E-02 |
| Normal-vs-Stage3 |
4.4403003496285E-10 |
| Normal-vs-Stage4 |
1.73006053927338E-12 |
| Stage1-vs-Stage2 |
1.495420E-03 |
| Stage1-vs-Stage3 |
6.183600E-01 |
| Stage1-vs-Stage4 |
2.544300E-02 |
| Stage2-vs-Stage3 |
4.776100E-04 |
| Stage2-vs-Stage4 |
2.44479999998992E-05 |
| Stage3-vs-Stage4 |
1.024620E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.59872115546023E-14 |
| Normal-vs-AfricanAmerican |
2.628200E-04 |
| Normal-vs-Asian |
8.01914090686751E-13 |
| Caucasian-vs-AfricanAmerican |
2.171000E-01 |
| Caucasian-vs-Asian |
1.833620E-01 |
| AfricanAmerican-vs-Asian |
8.385700E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.33310029681866E-11 |
| Normal-vs-Female |
4.14579481855526E-11 |
| Male-vs-Female |
4.131600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.7785772854495E-12 |
| Normal-vs-Age(41-60Yrs) |
2.74430034252759E-10 |
| Normal-vs-Age(61-80Yrs) |
5.99579996762856E-09 |
| Normal-vs-Age(81-100Yrs) |
5.262900E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.521200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.051000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.241200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.049000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.455600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.055400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.55289999999831E-05 |
| Classical-VS-Follicular |
9.39129999988353E-07 |
| Classical-VS-Other |
2.342600E-01 |
| Classical-VS-Normal |
1.63125069008174E-12 |
| Tall-VS-Follicular |
2.56259458097929E-11 |
| Tall-VS-Other |
7.809800E-01 |
| Tall-VS-Normal |
3.33066907387547E-16 |
| Follicular-VS-Other |
5.193200E-04 |
| Follicular-VS-Normal |
2.659800E-02 |
| Other-VS-Normal |
4.06360000000383E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.89560000608236E-09 |
| Normal-vs-N1 |
4.44089209850063E-15 |
| N0-vs-N1 |
5.50929999999505E-05 |
|
|
